We closed trading on 03 Mar 2026 with 1558.HK stock at HK$15.88, down 0.08 from the prior close. Volume was elevated at 19.31M shares, 2.08x average, suggesting active selling followed by bid support near the day low HK$15.52. The move leaves a tactical oversold bounce setup for traders who want a defined risk entry on the Hong Kong Stock Exchange (HKSE). We review price action, valuation, Meyka AI grade and practical price targets for both short-term bounce traders and medium-term investors.

Price action and market close detail for 1558.HK stock

YiChang HEC ChangJiang Pharmaceutical (1558.HK) finished the session at HK$15.88 on the HKSE. Today’s range was HK$15.52–HK$16.18, with an opening print at HK$16.14. Year high is HK$17.74 and year low is HK$7.92. Relative volume was 2.08, with trade size 19.31M versus average volume 9.30M. The intraday bid at the day low shows buyers stepping in, which supports an oversold bounce scenario rather than a broad capitulation.

Why this looks like an oversold bounce opportunity

Price sits near the 50-day average of HK$15.09 and above the 200-day average of HK$11.38, which often supports bounces. The stock pulled back from the year high HK$17.74, creating short-term selling pressure. Elevated volume plus a small close below intraday highs suggests exhaustion rather than trend reversal. For tactical traders, a bounce attempt off HK$15.52 offers a clear entry with a tight stop under that level.

Valuation and fundamentals: 1558.HK stock analysis

YiChang HEC reports EPS HK$0.60 and a trailing PE of 26.47. Market cap is HK$13.97B. Key ratios include PB 1.44 and ROE 5.87%. Dividend per share is HK$1.44 (dividend yield reported ~10.32% TTM), but payout figures show irregular cash flow patterns and a payout ratio flagged at 0.00. Free cash flow per share is negative at -HK$1.24, and days sales outstanding are long at 211 days. These metrics support a measured sizing approach for mean-reversion trades.

Meyka AI rates 1558.HK with a score out of 100 and forecast

Meyka AI rates 1558.HK with a score out of 100 at 69.69 (Grade B | HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects HK$15.75 in one year, implying -0.82% versus the current HK$15.88. The model shows HK$20.52 in three years (+29.22%) and HK$25.27 in five years (+59.06%). Forecasts are model-based projections and not guarantees. See company site and profile for filings company site and market data Reuters profile.

Risks, catalysts and sector context for 1558.HK stock

Risks include slowed revenue growth (FY2024 revenue down 40.84% year), stretched receivables and inventory days, and volatile free cash flow. Catalysts include new product approvals, Alibaba Health partnership projects, and improved working capital. Healthcare peers trade at an average PE near 27.65; 1558.HK’s PE 26.47 is in line with sector multiples. Monitor upcoming quarterly results and any regulatory updates in China as decisive catalysts.

Trade plan and realistic price targets for an oversold bounce

Tactical entry: buy on a confirmed bounce above HK$15.80–HK$16.00 with a stop at HK$15.00 (loss ~-5.69%). Near-term take-profit: HK$17.50 (target upside +10.17%). Medium-term target (12–36 months) aligns with Meyka AI’s 3-year HK$20.52 forecast. Position size should account for cash flow risks and inventory cycles. Use a trailing stop if price breaks past the year high HK$17.74.

Final Thoughts

1558.HK stock closed the market at HK$15.88 on 03 Mar 2026 and shows a classic oversold bounce setup: elevated volume, support near the 50-day average, and buyers at the day low. Fundamentals present mixed signals — a trailing PE of 26.47, PB 1.44, but negative free cash flow per share -HK$1.24 and long receivable days. Meyka AI’s model projects HK$15.75 in one year (implied -0.82%) and HK$20.52 in three years (+29.22%). For traders, a defined entry above HK$15.80 with a stop at HK$15.00 and a near-term target of HK$17.50 offers controlled risk-reward. For investors, the stock merits further monitoring of earnings, cash flow trends and regulatory updates before increasing exposure. Meyka AI, an AI-powered market analysis platform, flags this name as HOLD per the proprietary grade and stresses model-based forecasts are not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.